[go: up one dir, main page]

AR121805A1 - Anticuerpo anti-cd47 y usos del mismo - Google Patents

Anticuerpo anti-cd47 y usos del mismo

Info

Publication number
AR121805A1
AR121805A1 ARP210100941A ARP210100941A AR121805A1 AR 121805 A1 AR121805 A1 AR 121805A1 AR P210100941 A ARP210100941 A AR P210100941A AR P210100941 A ARP210100941 A AR P210100941A AR 121805 A1 AR121805 A1 AR 121805A1
Authority
AR
Argentina
Prior art keywords
antibody
same
antigen
treating
preparing
Prior art date
Application number
ARP210100941A
Other languages
English (en)
Inventor
Cai Yu
Yang Yizhen
Li Xiong
Yang Xianwen
Ren Yongxin
Su Wei-Guo
Original Assignee
Hutchison Medipharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hutchison Medipharma Ltd filed Critical Hutchison Medipharma Ltd
Publication of AR121805A1 publication Critical patent/AR121805A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención provee un anticuerpo anti-CD47 o un fragmento del mismo que se une al antígeno, un método de preparación del mismo y el uso para tratar o prevenir enfermedades relacionadas con CD47.
ARP210100941A 2020-04-10 2021-04-09 Anticuerpo anti-cd47 y usos del mismo AR121805A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202010282924 2020-04-10

Publications (1)

Publication Number Publication Date
AR121805A1 true AR121805A1 (es) 2022-07-13

Family

ID=78024001

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210100941A AR121805A1 (es) 2020-04-10 2021-04-09 Anticuerpo anti-cd47 y usos del mismo

Country Status (16)

Country Link
US (1) US20230151110A1 (es)
EP (1) EP4132976A4 (es)
JP (1) JP7748389B2 (es)
KR (1) KR20230015331A (es)
CN (1) CN115698066A (es)
AR (1) AR121805A1 (es)
AU (1) AU2021251989A1 (es)
BR (1) BR112022020555A2 (es)
CA (1) CA3179373A1 (es)
CL (1) CL2022002727A1 (es)
IL (1) IL297171A (es)
MX (1) MX2022012588A (es)
PE (1) PE20230765A1 (es)
PH (1) PH12022552688A1 (es)
TW (1) TWI869582B (es)
WO (1) WO2021204281A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR127273A1 (es) * 2021-10-09 2024-01-03 Hutchmed Ltd Anticuerpos biespecíficos que se unen específicamente a cd47 y her2 y usos de los mismos

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8691780B2 (en) * 2005-02-17 2014-04-08 The Board Of Trustees Of The Leland Stanford Junior University Txr1 and enhanced taxane sensitivity based on the modulation of a pathway mediated thereby
MX2015010115A (es) 2013-02-06 2016-05-31 Inhibrx Llc Anticuerpos cd47 de no agotamiento de plaquetas y no agotamiento de globulos rojos y metodos de uso de los mismos.
JP6885606B2 (ja) 2015-09-18 2021-06-16 アーチ オンコロジー, インコーポレイテッドArch Oncology, Inc. 治療用ｃｄ４７抗体
GB2558131B (en) * 2015-09-21 2021-05-19 Surface Oncology Inc Anti-CD47 antibodies and methods of use
CN106117354B (zh) * 2016-06-24 2020-01-14 安徽未名细胞治疗有限公司 一种全人源抗CD47的全分子IgG抗体及其应用
CN107955071B (zh) * 2016-10-18 2021-03-26 上海赛远生物科技有限公司 人源抗人cd47抗体及其编码基因与应用
EP4124343A1 (en) 2016-10-20 2023-02-01 I-Mab Biopharma US Limited Novel cd47 monoclonal antibodies and uses thereof
NZ761568A (en) 2017-08-02 2022-11-25 Phanes Therapeutics Inc Anti-cd47 antibodies and uses thereof
CN109422811A (zh) 2017-08-29 2019-03-05 信达生物制药(苏州)有限公司 抗cd47抗体及其用途
CN108503708B (zh) * 2017-09-01 2021-07-30 北京智仁美博生物科技有限公司 抗人cd47抗体及其用途
EP3743108A4 (en) 2018-01-24 2022-01-26 Nanjing Legend Biotech Co., Ltd. ANTI-CD47 ANTIBODIES THAT DO NOT CAUSE SIGNIFICANT RBC AGGLUTINATION
US11987627B2 (en) * 2018-08-31 2024-05-21 Nanjing Sanhome Pharmaceutical Co., Ltd. Anti-CD47 antibody and application thereof
CN110066336B (zh) * 2019-05-12 2021-11-09 杭州科兴生物科技有限公司 抗cd47单克隆抗体、片段及其医药用途
AR127270A1 (es) * 2021-10-09 2024-01-03 Hutchmed Ltd Formulación de anticuerpos anti-cd47
AR127271A1 (es) * 2021-10-09 2024-01-03 Hutchmed Ltd Anticuerpos biespecíficos que se unen específicamente a cd47 y cd20, y usos de los mismos
AR127273A1 (es) * 2021-10-09 2024-01-03 Hutchmed Ltd Anticuerpos biespecíficos que se unen específicamente a cd47 y her2 y usos de los mismos

Also Published As

Publication number Publication date
CL2022002727A1 (es) 2023-05-26
IL297171A (en) 2022-12-01
EP4132976A4 (en) 2024-05-01
US20230151110A1 (en) 2023-05-18
WO2021204281A1 (en) 2021-10-14
BR112022020555A2 (pt) 2022-12-06
PE20230765A1 (es) 2023-05-09
AU2021251989A1 (en) 2022-11-17
EP4132976A1 (en) 2023-02-15
TWI869582B (zh) 2025-01-11
KR20230015331A (ko) 2023-01-31
CN115698066A (zh) 2023-02-03
JP2023521790A (ja) 2023-05-25
CA3179373A1 (en) 2021-10-14
MX2022012588A (es) 2022-11-07
PH12022552688A1 (en) 2022-12-19
TW202140565A (zh) 2021-11-01
JP7748389B2 (ja) 2025-10-02

Similar Documents

Publication Publication Date Title
UY39798A (es) Anticuerpos anti-ccr8 y usos de los mismos
CL2024002250A1 (es) Uso de anticuerpo anti-vd1 para tratar cáncer, una enfermedad infecciosa o una enfermedad inflamatoria.
UY40829A (es) Anticuerpos anti-phf-tau y sus usos
CL2018003563A1 (es) Anticuerpos anti-c5 y usos de los mismos.
CL2020002103A1 (es) Anticuerpos anti-htra1 y metodos de uso de los mismos. (divisional solicitud 201801139)
CL2022002829A1 (es) Anticuerpo anti-ox40 y usos del mismo
AR120886A1 (es) Anticuerpos anti-fgfr2b
UY37591A (es) Conjugados de fármaco anticuerpo
CR20160132A (es) Composiciones y método para tratar condiciones asociadas con el complemento
CL2023000741A1 (es) Anticuerpo anti-nectina-4, conjugado que lo incluye y aplicación de los mismos.
BR112021022089A2 (pt) Materiais e métodos para modulação da imunidade mediada por células t
MX2017012615A (es) Anticuerpo anti-notch4 humano.
CL2021001607A1 (es) Anticuerpos anti-pmel17 y conjugados de los mismos
BR112021013397A2 (pt) Anticorpos anti-tigit
MX2019002929A (es) Biomarcadores de arn para angioedema hereditario.
CO2023000557A2 (es) Anticuerpos y métodos para tratar enfermedades asociadas a claudina
CR20220330A (es) Anticuerpos anti-ly6g6d y métodos de uso.
MX2022002672A (es) Anticuerpo anti-vsig4 o fragmento de union a antigeno y usos del mismo.
CU24556B1 (es) Anticuerpos anti-basigin humanizados
CL2024003486A1 (es) Anticuerpo anti-b7h3 y usos del mismo
BR112022001336A8 (pt) Anticorpo biespecífico anti-her2/anti-4-1bb e uso do mesmo
AR121805A1 (es) Anticuerpo anti-cd47 y usos del mismo
MX2020003806A (es) Anticuerpos monoclonales de adn que se dirigen a ctla-4 para el tratamiento y prevención del cáncer.
CO2022009246A2 (es) Anticuerpo anti-c5 para el tratamiento del trastorno del espectro de la neuromielitis óptica
CL2022000752A1 (es) Molécula de unión específica para lif y uso de la misma